The agency’s assessment indicates gaps in how donors were evaluated for health conditions that could pose risks to recipients of plasma-derived products. Health Canada did not publicly name the specific disorder risks cited in the review, but the probe focused on whether screening protocols were consistently applied and whether donor information was accurately recorded and interpreted by clinic staff.
Grifols operates a plasma donation center on Taylor Avenue in Winnipeg, where the company collects plasma used to manufacture therapies for a range of medical conditions. The facility has been a long-standing site in the company’s Canadian network, drawing donors from the region to contribute plasma under a variety of screening criteria intended to ensure product safety.
Health Canada confirmed it conducted an inspection of the Grifols clinic as part of its routine oversight of facilities involved in plasma collection and processing. The agency emphasized that its work aims to ensure donor eligibility standards and product safety, noting that inspections can result in corrective actions or enforcement measures if non-compliance is identified.
The scope of the investigation and the specifics of any corrective steps were not fully disclosed in public statements. Health Canada indicated it would work with Grifols to address any deficiencies and would monitor the facility to ensure ongoing compliance with applicable federal rules governing plasma collection, testing, and the handling of donor information.
Requests for comment from Grifols Canada were not immediately returned. A spokesperson in Winnipeg familiar with the clinic described the operation as a standard plasma collection site, noting that donors are subject to medical history reviews, physical examinations, and testing policies designed to minimize risk to recipients. The clinic did not publicly disclose the particular donor screening measures in use at the time of the investigation.
From a regulatory standpoint, Health Canada’s oversight of plasma collection facilities is part of a broader framework intended to protect the safety and supply of blood and blood-derived products. The agency’s role includes ensuring that screening, testing, and processing meet established safety criteria and that any deviations are addressed swiftly.
Health Canada has historically required plasma collection facilities to maintain documented evidence of donor eligibility, including medical histories, clinical assessments, and laboratory testing results. In cases where concerns about donor suitability arise, facilities may be obligated to halt certain collections or revise procedures until compliance is restored.
The Winnipeg clinic remains operational while the regulatory process continues, with health authorities emphasizing that patient safety remains the priority. Grifols, a multinational company, operates multiple plasma centers across Canada and globally, all subject to national regulatory regimes that govern donor recruitment, screening, and product handling.
Experts observing plasma collection programs note that donor eligibility criteria can be complex, balancing the need for adequate plasma supply with stringent safety standards. They say incidents where donors with higher risk profiles are inadvertently approved highlight the importance of robust training, clear protocols, and consistent record-keeping within collection sites.
Health Canada’s forthcoming updates or any published compliance actions will determine the next steps for the Winnipeg clinic. The agency has stated its commitment to transparency and to providing the public with information about safety investigations as they proceed. For now, officials reiterate that safety of plasma products and the integrity of the donation process remain the central public-interest concern guiding regulatory oversight.